Table 1.
Vaccine potency of recombinant BoNT and BoNT-derivatives in the mouse model of botulism
| Vaccine Primary & Boost (μg)a | Challenge BoNT serotype | Survivors/Challenged Units of BoNT/A LD50 challenge (U)b |
|||
|---|---|---|---|---|---|
| 103 U | 104 U | 105 U | 106 U | ||
| Experiment 1 | |||||
| M-BoNT/A1 (0.3) | A1 | 10/10 | -c | - | - |
| A2 | 10/10 | - | - | - | |
| M-BoNT/A1W d (0.3) | A1 | 10/10 | - | - | - |
| A2 | 10/10 | - | - | - | |
| HCC/A1W (0.1) | A1 | 7/10 | - | - | - |
| A2 | 6/10 | - | - | - | |
| Alum | A1 | 0/5 | - | - | - |
| Experiment 2 | |||||
| M-BoNT/A1 (0.3) | A2 | - | 8/8 | 8/8 | 5/9 |
| M-BoNT/A1W (0.3) | A2 | - | 8/8 | 8/8 | 3/9 |
| Alum | A2 | - | - | - | 0/5 |
| Experiment 3 | |||||
| M-BoNT/A1W (0.3) | A1 | - | - | - | 10/10 |
| M-LCHCN/A1 (0.2) | A1 | - | - | - | 10/10 |
| M-LCHCN (0.2) + HCC/A1W (0.1) | A1 | - | - | - | 10/10 |
| HCC/A1W (0.3) | A1 | - | - | 7/10 | - |
| M-BoNT/A1W (0.3) | A(subtype cocktail)e | - | - | 10/10 | - |
| M-LCHCN/A1 (0.2) | A(subtype Cocktail) | - | - | 10/10 | - |
| M-LCHCN/A1 (0.2) + HCC/A1W (0.1) | A(subtype Cocktail) | - | - | 9/10 | - |
| HCC/A1W (0.3) | A(subtype Cocktail) | - | - | 7/10 | - |
| Alum | A(subtype Cocktail) | - | 0/5 | - | - |
a
Mice were immunized IP with the indicated vaccine with alhydrogel as adjuvant. Vaccines were administered on day 1 and 14, blood was collected on day 21, and mice were challenged as indicated on day 26
b
U = One half-lethal dose of a botulinum neurotoxin at 72 h post challenge is defined as 1 mouse LD50
c
– = not determined
d
W = W1266A mutation within the ganglioside binding domain of HC/A1
e
A(subtype cocktail) = 25,000 LD50 U of BoNT/A2/A3/A5 and/A6 (total 100,000 LD50 U)